Clonazepam tablets for seizure disorders and panic disorder treatment

Clonazepam tablets contain clonazepam, a benzodiazepine used to treat certain seizure disorders and panic disorder in adults. It works by enhancing gamma aminobutyric acid (GABA) activity in the brain, which helps reduce seizure activity and panic attacks. The medication is taken orally, with absorption occurring rapidly and nearly completely.

Clonazepam tablets are indicated for:

• Treatment of seizure disorders including Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. It may also be used in patients with absence seizures (petit mal) who have not responded to succinimides.
• Treatment of panic disorder, with or without agoraphobia, in adults as defined by DSM-V criteria. Panic disorder involves recurrent unexpected panic attacks and associated behavioral changes.

The efficacy in long-term use beyond 9 weeks has not been systematically studied.

Clonazepam

Clonazepam is believed to work by enhancing the activity of gamma aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. This action helps suppress seizures and reduce symptoms of panic by calming overly active nerve signals in the brain.

The tablets are administered orally. Dosing varies according to the indication, patient response, and tolerability. Treatment initiation and discontinuation should be done cautiously with gradual dose adjustments.

For panic disorder, clinical studies used doses ranging from 0.5 mg to 4 mg per day, with an average effective dose around 1 to 2.3 mg daily. Titration and tapering schedules should be individualized to reduce withdrawal risk.

Prescribers should periodically reassess the need for continued treatment, especially beyond 9 weeks.

• Known hypersensitivity to clonazepam or other benzodiazepines.
• Significant liver disease due to impaired metabolism.
• Acute narrow-angle glaucoma; may be used in open-angle glaucoma if appropriately treated.

• Concomitant use with opioids: May cause profound sedation, respiratory depression, coma, or death. Use only when alternatives are inadequate with minimal dosages and close monitoring.
• Abuse, misuse, addiction: Clonazepam carries risk of dependence and addiction, especially when combined with other substances like alcohol or opioids. Assess patient risk and monitor throughout treatment.
• Dependence and withdrawal: Physical dependence may develop. Abrupt discontinuation or rapid dose reduction can cause life-threatening withdrawal symptoms, including seizures. Gradual tapering is essential.
• Impaired cognitive/motor performance: May impair alertness and coordination; patients should avoid hazardous activities such as driving until effects are known.
• Suicidal behavior and ideation: Increased risk has been observed with antiepileptic drugs including clonazepam. Monitor patients for emerging or worsening depression or suicidal thoughts.
• Neonatal effects: Use in late pregnancy may cause sedation or withdrawal symptoms in newborns requiring monitoring.

• Common: sedation, increased salivation, dizziness, unsteadiness, and cognitive impairment.
• Serious: paradoxical reactions including agitation, irritability, aggression, hallucinations, and psychosis; respiratory depression especially in compromised patients; withdrawal seizures; and benzodiazepine dependence.

• Concomitant use with opioids significantly increases risks of sedation, respiratory depression, and death.
• Other CNS depressants, including alcohol, may increase sedation and impairment risks.
• Metabolism involves cytochrome P-450 enzymes including CYP3A; inhibitors or inducers of these enzymes may affect clonazepam levels.

Use late in pregnancy can cause neonatal sedation and withdrawal symptoms that may include respiratory depression, lethargy, irritability, tremors, and feeding difficulties. Neonates exposed to clonazepam during pregnancy or labor require monitoring for these effects.

Overdose symptoms can include excessive sedation, respiratory depression, coma, and death. Management involves supportive care and monitoring of respiratory and cardiovascular function.